Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition | Zendy

Stephan J. Matissek | Zendy; Weiguo Han | Zendy; Mona Karbalivand | Zendy; Mohamed Sayed | Zendy; Brendan M. Reilly | Zendy; Shayna Mallat | Zendy; Shimaa Ghazal | Zendy; Manit Munshi | Zendy; Guang Yang | Zendy; Steven P. Treon | Zendy; Sarah R. Walker | Zendy; Sherine F. Elsawa | Zendy

Open Access

Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition

Author(s) -

Stephan J. Matissek,

Weiguo Han,

Mona Karbalivand,

Mohamed Sayed,

Brendan M. Reilly,

Shayna Mallat,

Shimaa Ghazal,

Manit Munshi,

Guang Yang,

Steven P. Treon,

Sarah R. Walker,

Sherine F. Elsawa

Publication year - 2020

Publication title -

epigenomics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.265

H-Index - 60

eISSN - 1750-1911

pISSN - 1750-192X

DOI - 10.2217/epi-2020-0189

Subject(s) - panobinostat , histone deacetylase , cancer research , waldenstrom macroglobulinemia , epigenetics , vorinostat , bet inhibitor , epigenetic therapy , biology , macroglobulinemia , ibrutinib , histone deacetylase inhibitor , epigenome , lymphoma , histone , bromodomain , immunology , multiple myeloma , dna methylation , leukemia , genetics , gene expression , chronic lymphocytic leukemia , gene

Aim: Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by overproduction of monoclonal IgM. To date, there are no therapies that provide a cure for WM patients, and therefore, it is important to explore new therapies. Little is known about the efficiency of epigenetic targeting in WM. Materials & methods: WM cells were treated with BET inhibitors (JQ1 and I-BET-762) and venetoclax, panobinostat or ibrutinib. Results: BET inhibition reduces growth of WM cells, with little effect on survival. This finding was enhanced by combination therapy, with panobinostat (LBH589) showing the highest synergy. Conclusion: Our studies identify BET inhibitors as effective therapy for WM, and these inhibitors can be enhanced in combination with BCL2 or histone deacetylase inhibition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research